Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Teva Pharmaceutical (GB:0LER)
LSE:0LER
Teva Pharmaceutical (0LER) Share Price & Analysis
0 Followers
0LER Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$7.10 - $14.41
Previous Close$13.07
Volume7.85K
Average Volume (3M)82.64K
Market Cap
$14.65B
Enterprise Value$32.19B
Total Cash (Recent Filing)$3.23B
Total Debt (Recent Filing)$20.15B
Price to Earnings (P/E)-27.7
Beta1.98
Next EarningsN/A
EPS EstimateN/A
Last Dividend Ex-Date
Nov 27, 2017Dividend YieldN/A
Share Statistics
EPS (TTM)-0.47
Shares Outstanding1,121,094,011
10 Day Avg. Volume8,478
30 Day Avg. Volume82,639
Standard Deviation0.16
R-Squared0.11
Alpha0.00160
Financial Highlights & Ratios
Price to Book (P/B)-0.97
Price to Sales (P/S)2.97
Price to Cash Flow (P/CF)3.10
P/FCF Ratio1.80
Enterprise Value/Market CapN/A
Enterprise Value/Revenue2.03
Enterprise Value/Gross Profit4.21
Enterprise Value/Ebitda17.71
Forecast
1Y Price Target
$15.71Price Target Upside20.23% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering8
Teva Pharmaceutical News
PremiumCompany Announcements
Teva Pharmaceutical Revamps Financial Reporting Structure
Bulls Say, Bears Say
Bulls Say
Financial Health ImprovementAn improving capital structure with a targeted net debt to EBITDA ratio suggests Teva is on a path to stronger financial health.
Market ExpansionThe licensing agreement with mAbxience allows Teva to tap into multiple global markets, including Europe and the United States, presenting significant market potential.
Strategic Business DevelopmentTeva's strategic partnership with mAbxience for in-licensing an oncology biosimilar expands its treatment options and shows the strength of its business development efforts.
Bears Say
Competitive PressuresNorth America generics are facing strong competition, particularly against gRevlimid, causing a significant drop in sales.
Financial IrregularitiesTeva has made a substantial correction to its financial statements due to an understatement of contingent consideration liability.
Operational ChallengesThe anticipated rise in operating expenses could pressure the company’s profitability and overall financial health.
---
Options Prices
Currently, No data available
---
Ownership Overview
0.83% Insiders
14.72% Mutual Funds
2.80% Other Institutional Investors
81.65% Public Companies and
Individual Investors
0LER FAQ
What was Teva Pharmaceutical’s price range in the past 12 months?
Teva Pharmaceutical lowest share price was $7.10 and its highest was $14.41 in the past 12 months.
What is Teva Pharmaceutical’s market cap?
Currently, no data Available
When is Teva Pharmaceutical’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Teva Pharmaceutical’s earnings last quarter?
Currently, no data Available
Is Teva Pharmaceutical overvalued?
According to Wall Street analysts Teva Pharmaceutical’s price is currently Undervalued.
Does Teva Pharmaceutical pay dividends?
Teva Pharmaceutical pays a Quarterly dividend of $0.07 which represents an annual dividend yield of N/A. See more information on Teva Pharmaceutical dividends here
What is Teva Pharmaceutical’s EPS estimate?
Teva Pharmaceutical’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Teva Pharmaceutical have?
Teva Pharmaceutical has 1,120,992,400 shares outstanding.
What happened to Teva Pharmaceutical’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Teva Pharmaceutical?
Among the largest hedge funds holding Teva Pharmaceutical’s share is Slate Path Capital LP. It holds Teva Pharmaceutical’s shares valued at 274M.
---
Teva Pharmaceutical Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$15.71 (20.23% Upside)
$15.71 (20.23% Upside)
Blogger Sentiment
Bullish
GB:0LER Sentiment 80%
Sector Average 70%
Sector Average 70%
Insider Transactions
Sold Shares
Worth $4.0M over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
55.05%
12-Months-Change
Fundamentals
Return on Equity
-6.84%
Trailing 12-Months
Asset Growth
-1.20%
Trailing 12-Months
Company Description
Teva Pharmaceutical
Teva Pharmaceutical Industries Ltd. engages in the development and production of medicines. Its products include medicines for cardiovascular diseases, pain relievers, obesity, cancer and supportive care, infectious diseases and human immunodeficiency viruses, and colds and coughs. The company was founded in 1901 and is headquartered in Petah Tikva, Israel.
---
0LER Stock 12 Months Forecast
Average Price Target
$15.71
▲(20.23% Upside)
Technical Analysis
Best Analysts Covering 0LER
1 Year
1 Year Success Rate
10/16 ratings generated profit
1 Year Average Return
+14.81%
assigned a buy rating 15 days ago
Copying Balaji Prasad's trades and holding each position for 1 Year would result in 62.50% of your transactions generating a profit, with an average return of +14.81% per trade.
---